- $31.73m
- $72.46m
- $26.55m
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform
Brief: Celularity - Enters Settlement Agreement With Helena On May 21, 2026
Brief: Nexgel New Strategic Partner, Sequence Lifescience, Leads Financing With $5.5 Million To Complete Acquisition Of Celularity Degenerative Disease Segment
Brief: Celularity Announces Receipt Of Nasdaq Notice Regarding Late Form 10-K Filing
Brief: Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026 - SEC Filing
Brief: Celularity Receives $12.2 Million From Sale Of New Jersey Net Operating Losses
Brief: Celularity Files For Offering Of Up To 14.1 Million Shares Of Class A Common Stock
Brief: Celularity - Enters Securities Purchase Agreement For Private Placement
Brief: Celularity Receives Nasdaq Notice Regarding Form 10-Q
Brief: Celularity Completes Major Balance Sheet Restructuring
Brief: Celularity Announces Chief Financial Officer Transition
Brief: Celularity Files For Non-Timley 10-K - SEC Filing
Brief: Celularity enters into standby equity purchase agreement with Ya Ii Pn
Brief: Celularity Inc - On Feb 12, Enters Binding Term Sheet Or Rwi Binding Term Sheet, With Resorts World Inc Pte Ltd
Brief: Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Brief: Celularity Announces Receipt Of Nasdaq Notification